What Immunal treats: main uses and benefits

Immunal is an herbal preparation derived from the juice of the Echinacea purpurea plant. It is primarily used to support the body's natural defense mechanisms and is classified as an immunostimulant.

Main Uses

The preparation is indicated for the following conditions:

• Prevention of Respiratory Infections: It is used as a supportive measure to help the body resist common viral infections, such as the common cold and influenza, particularly during seasons when these illnesses are prevalent.
• Supportive Treatment for Recurrent Infections: It may be used as an adjunct in the long-term treatment of chronic or frequently recurring infections of the respiratory and urinary tracts.
• Strengthening the Immune System: It is often recommended for individuals with a weakened immune system caused by factors such as physical exhaustion, environmental stressors, or during the recovery period following a prolonged illness.

Benefits

The primary benefits of Immunal are associated with its active components, specifically polysaccharides and flavonoids found in Echinacea. These substances contribute to several physiological processes:

• Non-Specific Immune Activation: The preparation stimulates the activity of white blood cells (leukocytes and macrophages), which are responsible for identifying and neutralizing pathogens.
• Viral and Bacterial Resistance: By enhancing the cellular immune response, it helps the body limit the replication of viruses and bacteria, potentially shortening the duration of illness.
• Anti-inflammatory Properties: The active ingredients may exert a mild anti-inflammatory effect, which can help alleviate the systemic symptoms associated with respiratory infections.

Regulatory References

1. European Union herbal monograph on Echinacea purpurea

The eligibility criteria for Иммунал (or equivalent Echinacea purpurea extract preparations) are strictly defined by official regulatory documentation.

Population Eligibility Status

Population Status	Regulatory Rule
Approved Use	Adults and Adolescents over 12 years of age.
Not Recommended	Children below 12 years (due to safe use not being sufficiently documented).
Not Recommended	Use during Pregnancy or Lactation (safety not established).

The medicine is absolutely contraindicated in patients with specific conditions. Use is prohibited for individuals with known Hypersensitivity to the active ingredient or to plants of the Asteraceae (Compositae) family (e.g., ragweed, daisies).

Furthermore, Иммунал must not be used by individuals with systemic or immune-related disorders, including Progressive Systemic Disorders (like Tuberculosis or Sarcoidosis), Autoimmune Diseases (like Multiple Sclerosis), Immunodeficiencies (like HIV or AIDS), Diseases of the white blood cell system (like Leukoses), and those undergoing Immunosuppression (such as cytostatic therapy). Atopic Patients must seek medical consultation prior to use due to the potential risk of allergic reaction.

Interactions with other medicines and products

Official regulatory information for Immunal (Echinacea purpurea extract) establishes key restrictions and potential interactions, primarily categorized by pharmacodynamic interference and pharmacokinetic enzyme modulation.

Contraindicated and Restricted Combinations

Due to its reported immunomodulating properties, Immunal is not recommended for use with medications that suppress the immune system. Concomitant use is restricted with immunosuppressive drugs such as ciclosporin and methotrexate, as the herbal product may counteract their therapeutic effect.

Additionally, the product is not recommended for individuals with pre-existing conditions involving immune dysregulation, including progressive systemic disorders, autoimmune diseases (e.g., multiple sclerosis), immunodeficiencies, or existing immunosuppression.

Potential Pharmacokinetic Interactions

The product may have the potential to affect metabolic clearance pathways. Regulatory documentation indicates a possible interaction with drugs metabolized by Cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP1A2. Caution should be exercised when co-administering substances that are sensitive substrates of these enzymes. Specific studies have also noted an increase in the apparent clearance of S-warfarin.

Иммунал, an extract derived from Echinacea purpurea, exerts its effect primarily through immunomodulation by interacting with components of the innate immune system. The bioactive compounds, which include alkylamides and caffeic acid derivatives (like chicoric acid), are thought to target various immune cell types.

Constituents are observed to enhance the phagocytic activity of macrophages and polymorphonuclear leukocytes in tissue compartments, leading to increased clearance of particulate matter. This enhanced activity is coupled with the stimulation of macrophages to increase the production and release of cytokines, such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF- alpha), which are intercellular signaling proteins.

Alkylamides interact with the cannabinoid receptor 2 ( CB2), an interaction type classified as an agonist, which is hypothesized to mediate certain anti-inflammatory aspects. Furthermore, the extract is known to increase the activity of Natural Killer (NK) cells and promote the proliferation of lymphocytes. The collective downstream cascade results in systemic modulation of the acute phase immune response.

The administration of Иммунал (based on Echinacea purpurea extract) is governed by standardized instructions focusing on the mechanics of use, dosage, and duration. The medicinal product is for oral use and is available in both liquid oral solution (drops) and solid tablet formulations.

---

Standard Administration Guidelines

Entity	Guideline
Route	Oral use
Forms	Tablets, Oral Solution
Frequency	Typically taken in divided doses, such as three times daily.
Dose	Adults and adolescents over 12 years receive the standard labeled dose, which corresponds to 1 tablet or a measured amount of the liquid per administration.

---

Key Procedural and Duration Rules

Use is categorized as short-term only, and the regimen must not be used for more than 10 days. Administration should commence at the first signs of symptoms. It is essential to strictly adhere to the dose stated on the product labeling and not to exceed the daily limit.

---

Population-Specific Rule

The administration rules contain a specific age restriction: the product is not recommended for use in children below 12 years of age. If symptoms persist after the 10-day course, or if a high fever occurs, treatment must be discontinued.

Research Evidence / Overview of Studies for Иммунал

Evidence for Supportive Management of the Acute Common Cold

The clinical evaluation of Иммунал preparations has focused on conditions involving acute or disruptive cold episodes, where symptoms may be heightened or rapidly evolving. Studies in this area are primarily Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were conducted to explore how symptoms change over time and typically included generally healthy adults and children who had recently started experiencing cold symptoms.

Research examined how symptoms evolved in the observed populations, and some trials described patterns where the measured duration of the cold episode was shorter in the observed group compared to control groups. However, findings were mixed, and there were differences in reported symptom patterns across the entire body of evidence. Certainty remains low regarding a universal conclusion for acute use because the evidence is marked by heterogeneity, often linked to variability in the preparation used.

---

Evidence for Short-Term Cold Prevention

Research has also explored Иммунал preparations during periods of increased symptom activity, specifically focusing on short-term prevention. These studies were structured as prophylactic RCTs and monitored the incidence (frequency) of colds. Some studies monitored responses over defined time intervals and reported that the measured frequency of colds was lower in the observed group. Conversely, these observations were not uniformly described across all conducted trials.

Follow-up durations were limited, generally ranging only from one to four months, meaning long-term effects are not fully established regarding sustained or repeated use across multiple cold seasons. The core body of clinical research primarily included generally healthy adults and children over the age of four, and evidence is limited regarding patterns observed in older adults or individuals who have underlying health conditions.

---

What Remains Uncertain in the Research Landscape

The overall evidence base highlights several areas where more research is needed or where certainty remains low. A major factor is the variability of findings across different studies. Because Echinacea can be prepared in various ways, the evidence quality varies across studies, and results may not be interchangeable between different commercial products.

Key Studies & References

1. Echinacea: Usefulness and Safety - National Center for Complementary and Integrative Health (NCCIH) - NIH
2. Literature Review of the Effectiveness of Echinacea in Treating and Preventing the Common Cold - American Botanical Council

Common questions about Иммунал (FAQ)

---

Q: How quickly can I expect to see an effect from Иммунал?

Official product information suggests administration should commence at the first signs of cold symptoms. However, regulatory documents do not specify the exact time frame within which a patient should expect to notice an improvement or a measurable effect on the body.

---

Q: Is Иммунал safe for long-term use?

This product is intended for short-term use only, and the treatment course generally must not exceed 10 days. Use for prolonged periods, such as over eight weeks, has been associated with reports of a reduction in white blood cells, a condition called leucopenia. For this reason, continuous long-term use is not recommended.

---

Q: Can I take Иммунал with over-the-counter pain relievers like ibuprofen?

Official product documents advise caution when using Иммунал with certain medications, including those processed by the body's CYP3A4 and CYP1A2 enzymes. Since some over-the-counter pain relievers are processed by these enzyme systems, it is necessary to exercise caution when considering taking them concurrently.

---

Q: Does Иммунал interact with any common blood pressure medications?

Regulatory information indicates a potential for interaction with drugs that are sensitive substrates of the CYP3A4 and CYP1A2 enzymes in the liver. Since some common blood pressure medications fall into this category, it is necessary to exercise caution regarding concomitant use.

---

Q: What happens if I forget to take a dose of Иммунал?

If a dose is missed, official instructions indicate that patients should continue with their next scheduled dose at the usual time. The instructions advise against taking a double dose to make up for the missed one.

---

Q: Can Иммунал cause stomach issues?

Mild gastrointestinal symptoms have been reported with the use of Echinacea products. These can include feelings of nausea, general stomach pain, or minor digestive disturbances. The exact frequency of these adverse reactions is typically classified as not known from available data.

---

Q: Is it normal to feel a mild allergic reaction when starting Иммунал?

Regulatory documents list mild hypersensitivity reactions, such as rash or urticaria (hives), as possible adverse reactions. Although these reactions are documented in the safety profile, the exact incidence of them is not known. More serious allergic responses, such as anaphylactic shock, are rare but also documented.

---

Q: Why do people recommend Иммунал for seasonal changes?

The official regulatory indication for Иммунал is its use in the short-term prevention and treatment of the common cold. Since colds are often more prevalent during seasonal periods, the product is typically used during these times to support the body's natural immune defenses.

---

Q: Can Иммунал make me drowsy?

Drowsiness or other effects on the central nervous system are not typically listed as known adverse reactions in the official safety information. Regulatory bodies have also not reported specific studies concerning its effects on the ability to drive or operate machinery.

---

Q: Is it safe to take Иммунал when I already have a cold?

The product is indicated for the treatment of the common cold, but administration is recommended to start at the first signs. If symptoms worsen or persist for longer than 10 days, discontinuation of treatment is necessary.

---

Q: What happens if I accidentally take too much Иммунал?

In the event of an overdose, official product information advises consulting a doctor or pharmacist. If the liquid oral solution is taken in excess, this may result in alcohol intoxication due to its content, and medical consultation is required in such circumstances.

---

Q: Does Иммунал interact with mood stabilizers?

Regulatory documents note a potential for interaction with drugs processed by CYP450 enzymes in the body. Since many mood-stabilizing medications are substrates of these enzymes, medical consultation regarding concomitant use is required.

---

Q: Can I take Иммунал if I have asthma?

Patients with asthma or other allergic conditions are considered atopic patients. Official warnings state that atopic patients must seek medical consultation before using the product due to a possible increased risk of severe allergic reactions.

Safe and proper handling of all pharmaceutical products, including Иммунал, requires adherence to the manufacturer’s instructions as approved by governmental regulatory bodies. These instructions define the specific conditions necessary to maintain the drug’s potency and stability.

Storage & Disposal Requirements

Requirement	Specific Labeled Instruction (Иммунал)
Storage Temperature	The exact temperature range is not publicly available and must be verified on the product's official label.
Light/Moisture Protection	Products must be stored in the original container to protect against environmental degradation, unless otherwise directed.
Handling Constraints	General pharmaceutical practice requires storing the product out of the reach and sight of children.
Disposal	Disposal of expired or unused medication should follow local waste regulations, often utilizing community drug take-back programs or safe household disposal guidelines, such as those provided by the FDA or local authorities.